Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)

Thursday, May 18, 2017 12:06 PM UTC

SOUTH SAN FRANCISCO, Calif., May 18, 2017 -- Portola Pharmaceuticals Inc.^® (Nasdaq:PTLA) today announced that preclinical and clinical data on cerdulatinib in relapsed/refractory b-cell malignancies will be presented at the European Hematology Association (EHA), which is taking place from June 22-25 in Madrid, Spain.

Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulatinib inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies.

Details regarding the presentations follow.

Oral Presentation Details:

Presentation Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Complete Inhibition of SYK and JAK and Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B Cell Malignancies
Presenter: Paul Hamlin, M.D., Memorial Sloan-Kettering Cancer Center
Abstract Number: EHA22
Presentation Date and Time: June 25, 2017 from 9:00-9:15 a.m. UTC
Location: Hall A

Poster Presentation Details:

Presentation Title: IL-4 Increases Expression of Positive Regulators of BCR Signaling in CLL Which Can Be Overcome by Cerdulatinib
Presenter: Andrew Steele, Ph.D., Associate Professor, Medicine, University of Southampton
Abstract Number: P587
Presentation Date and Time: June 24, 2017 from 5:30 – 6:00 p.m. UTC
Location: Poster Hall (Hall 7)

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.

Investors:      
Ana Kapor
Portola Pharmaceuticals
[email protected]                         

Media:
Julie Normart 
Pure Communications 
[email protected] 
415.946.1087

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)

Editor's Picks

Welcome to EconoTimes